PDCD1 and classic Hodgkin lymphoma: During 2017–2019, a total of 77 cases with R/R cHL who received anti‐PD‐1 camrelizumab monotherapy (n = 26) or decitabine‐plus‐camrelizumab combination (n = 51) for the first time were included in this study.